IART240816P22500
- 0.66
- -0.14-17.50%
Integra Lifesciences Newsroom
JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $35
Morgan Stanley Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $25
A Quick Look at Today's Ratings for Integra Lifesciences(IART.US), With a Forecast Between $22 to $35
Integra Lifesciences (IART) Receives a Sell From Morgan Stanley
Truist Financial Reaffirms Their Hold Rating on Integra Lifesciences (IART)
Integra Lifesciences Analyst Ratings
Truist Adjusts Price Target on Integra LifeSciences Holdings to $26 From $32 After 'Big' H2 Guide Cut, Maintains Hold Rating
Integra Lifesciences Downgraded to Sell on Revised Guidance and Compliance Concerns
Buy Rating Affirmed for Integra Lifesciences Amidst Growth and Recovery Potential
Integra Lifesciences: Strategic Manufacturing Shifts Amid Supply Constraints – A Hold Rating Perspective
Truist Raises Price Target on Integra LifeSciences Holdings to $32 From $25, Maintains Hold Rating
Integra Lifesciences Sell Rating Justified by Production Delays and Overvalued Stock
Integra Lifesciences Analyst Ratings
Morgan Stanley Raises Price Target on Integra LifeSciences to $27 From $24, Keeps Underweight Rating
Integra Lifesciences: Hold Rating Justified by Operational Struggles and Competitive Underperformance
Integra Lifesciences Analyst Ratings
Integra Lifesciences Analyst Ratings
Oppenheimer Cuts Integra to Perform, Cites Boston Plant Delays
Wells Fargo Downgrades Integra Lifesciences to Equal-Weight, Lowers Price Target to $25
Integra Lifesciences (IART) Was Downgraded to a Hold Rating at Oppenheimer